4.8 Article

Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma

Journal

ONCOGENE
Volume 24, Issue 53, Pages 7850-7858

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1208912

Keywords

VPF; VPF/VEGF; mRNA stability; angiogenesis; renal cell carcinoma; VHL; HuR

Funding

  1. NCI NIH HHS [CA78383] Funding Source: Medline
  2. NHLBI NIH HHS [HL70567] Funding Source: Medline
  3. NIDDK NIH HHS [DK 02825] Funding Source: Medline

Ask authors/readers for more resources

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available